TY - JOUR
T1 - Safinamide as an adjunct therapy in older patients with Parkinson’s disease: a retrospective study
AU - Lo Monaco, Maria Rita
AU - Petracca, Martina
AU - Vetrano, Davide Liborio
AU - Di Stasio, Enrico
AU - Fusco, Domenico
AU - Ricciardi, Diego
AU - Laudisio, Alice
AU - Zuccala', Giuseppe
AU - Onder, Graziano
AU - Bentivoglio, Anna Rita
PY - 2020
Y1 - 2020
N2 - Background: Safinamide, as a levodopa adjunct, is effective in reducing motor fluctuations in Parkinson’s disease (PD) patients; however, scarce evidence is available regarding its use in older PD patients. Aim: To evaluate the safety and tolerability of safinamide as an adjunct therapy in patients aged ≥ 60 years with advanced PD. Methods: A retrospective study including 203 PD patients admitted to a geriatric day hospital, who were evaluated following an extensive clinical protocol. Safinamide use was categorized as never used, ongoing, and withdrawn. Potential correlations of Safinamide withdrawal were investigated in stepwise backward logistic regression models. Results: A total of 44 out of 203 participants were current or former users of Safinamide. Overall, 14 (32%) patients discontinued due to treatment-emergent adverse events (TEAEs). Withdrawal was not associated with older age. Conclusions: Safinamide as an adjunct therapy in patients aged ≥ 60 years with advanced PD was found to be safe and well-tolerated in older patients. There were no specific demographic or clinical characteristics associated with suspension.
AB - Background: Safinamide, as a levodopa adjunct, is effective in reducing motor fluctuations in Parkinson’s disease (PD) patients; however, scarce evidence is available regarding its use in older PD patients. Aim: To evaluate the safety and tolerability of safinamide as an adjunct therapy in patients aged ≥ 60 years with advanced PD. Methods: A retrospective study including 203 PD patients admitted to a geriatric day hospital, who were evaluated following an extensive clinical protocol. Safinamide use was categorized as never used, ongoing, and withdrawn. Potential correlations of Safinamide withdrawal were investigated in stepwise backward logistic regression models. Results: A total of 44 out of 203 participants were current or former users of Safinamide. Overall, 14 (32%) patients discontinued due to treatment-emergent adverse events (TEAEs). Withdrawal was not associated with older age. Conclusions: Safinamide as an adjunct therapy in patients aged ≥ 60 years with advanced PD was found to be safe and well-tolerated in older patients. There were no specific demographic or clinical characteristics associated with suspension.
KW - Older patients
KW - Parkinson’s disease
KW - Safinamide
KW - Older patients
KW - Parkinson’s disease
KW - Safinamide
UR - http://hdl.handle.net/10807/149276
UR - http://link.springer.com/journal/volumesandissues/40520
U2 - 10.1007/s40520-020-01469-4
DO - 10.1007/s40520-020-01469-4
M3 - Article
SN - 1594-0667
VL - 2020
SP - N/A-N/A
JO - Aging clinical and experimental research
JF - Aging clinical and experimental research
ER -